Irisin ameliorates diabetic kidney disease by restoring autophagy in podocytes

Abstract

AbstractMany studies have highlighted the importance of moderate exercise. While it can attenuate diabetic kidney disease, its mechanism has remained unclear. The level of myokine irisin in plasma increases during exercise. We found that irisin was decreased in diabetic patients and was closely related to renal function, proteinuria, and podocyte autophagy injury. Muscle‐specific overexpression of PGC‐1α (mPGC‐1α) in a mouse model is known to increase plasma irisin levels. The mPGC‐1α mice were crossed with db/m mice to obtain db/db mPGC‐1α+ mice in the present study. Compared to db/db mice without mPGC‐1α, plasma irisin was increased, and albuminuria and glomerular pathological damage were both alleviated in db/db mPGC‐1α+ mice. Impaired autophagy in podocytes was restored as well. Irisin inhibited the activation of the PI3K/AKT/mTOR signaling pathway in cultured human podocytes and improved damaged autophagy induced by high glucose levels. Then, db/db mice were treated with recombinant irisin, which had similar beneficial effects on the kidney as those in db/db mPGC‐1α+ mice, with alleviated glomerular injury and albuminuria. Moreover, the autophagy in podocytes was also significantly restored. These results suggest that irisin secreted by skeletal muscles protects the kidney from diabetes mellitus damage. It also restores autophagy in podocytes by inhibiting the abnormal activation of the PI3K/AKT/mTOR signaling pathway. Thus, irisin may become a new drug for the prevention and treatment of diabetic nephropathy.